Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Income from Continuing Operations (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Income from Continuing Operations data on record, last reported at 1006000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 10.82% year-over-year to 1006000.0; the TTM value through Sep 2025 reached 3633000.0, up 38.68%, while the annual FY2024 figure was 3628000.0, 71.99% up from the prior year.
  • Income from Continuing Operations reached 1006000.0 in Q3 2025 per CYCN's latest filing, up from 1672000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 12395000.0 in Q4 2022 and bottomed at 16176000.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 4971000.0, with a median of 1865000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 186.44% in 2022, then tumbled 114.48% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 14339000.0 in 2021, then surged by 186.44% to 12395000.0 in 2022, then crashed by 114.48% to 1795000.0 in 2023, then skyrocketed by 127.97% to 502000.0 in 2024, then plummeted by 300.4% to 1006000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 1006000.0 in Q3 2025, 1672000.0 in Q2 2025, and 1457000.0 in Q1 2025.